Abstract
Background: Malignant Mesothelioma (MM) is a rare and aggressive tumour of the pleura and peritoneum associated with short survival time and needs timely diagnosis which varies with different histological subtypes.
Aim: To evaluate the incidence and clinicomorphological features of malignant mesothelioma with emphasis on early diagnosis by cytology.
Materials and Methods: A total of 78 cases of malignant mesotheliomas of different sites encountered over a 2-year period were retrospectively analysed with regard to their cytological findings and subsequent histopathology subtyping and follow up with patient survival.
Results: Environmental asbestos exposure was found in 75.00% of patients. The pleura was the most common site of involvement (76 cases)with one case of pericardial and peritoneal mesothelioma. Epithelioid mesothelioma was the most common histological type (62 cases, 79.4%) followed by sarcomatoid, desmoplastic and biphasic (4 cases each, 6.4%)and deciduoid (2 cases, 3.2%). All the cases diagnosed on FNA/Effusion cytology were confirmed by histopathology and subtyping was done. Mean patient survival time was 9 months.
Conclusion: Malignant mesothelioma related to asbestos exposure is seen rampantly in active mining areas of Southern Rajasthan and is associated with poor survival rates, which emphasizes the need for early diagnosis and histological subtyping for better patient outcomes.
Keywords: Histological type;cytology; mesothelioma.
References
- Olsen NJ, Franklin PJ, Reid A, de Klerk NH, Threlfall TJ, Shilkin K, Musk B (2011) Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 195(5): 271–274
- Brims FJ, Maskell NA (2013) Prognostic factors for malignant pleural mesothelioma. Curr Respir Care Rep 2(2): 100–108.
- Kazan-Allen L (2005) Asbestos and mesothelioma: worldwide trends. Lung Cancer 49(Suppl 1): S3–S8.
- Ahmed I, Koulaouzidis A, Iqbal J, Tan WC. Malignant peritoneal mesothelioma as a rare cause of ascites: a case report. J Med Case Reports. 2008;2:121.
- Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, et al.Guidelines for pathologic diagnosis of malignant mesothelioma: A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317-31.
- Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, Sleith J, Hammond N, Threlfall T, Shilkin KB, de Klerk N (2011) Predicting survival in malignant mesothelioma. Eur Respir J 38(6): 1420–1424.
- Marinaccio A, Binazzi A, Marzio DD, Scarselli A, Verardo M, Mirabelli D, et al.Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J Cancer 2012;130:2146-54.
- Rusch VW. Clinical features and current treatment of diffuse malignant pleural mesothelioma. Lung Cancer 1995;12(Suppl 2):S127-46.
- Kawashima A, Libshitz HI. Malignant pleural mesothelioma: CT manifestations in 50 cases. Am J Roentgenol 1990;155:965-9. Back to cited text no. 14
- Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241-5.
- Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN (2010) The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol 38(12): 874–879.
- Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES (1997a) The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 111(1): 106–109.
- Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BW, Creaney J (2013) A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 45(1): 44–48.
- Pinelli V, Laroumagne S, Sakr L, Marchetti GP, Tassi GF, Astoul P (2012) Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma. J Thorac Oncol 7(3): 595–59.
- Walts AE, Hiroshima K, McGregor SM, Wu D, Husain AN, Marchevsky AM (2016) BAP1 immunostain and CDKN2A (p16) FISH analysis: clinical applicability for the diagnosis of malignant mesothelioma in effusions. Diagn Cytopathol 44(7): 599–606.
Corresponding Author
Dr Rini Bishnoi
Senior Demonstrator, Pathology Department, Government Medical College, Pali, India
DOI: https://dx.doi.org/10.18535/jmscr/v9i8.15
